{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:56Z","timestamp":1762900076124,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001661","name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients with glioblastoma (GBM) or brain metastases (MET) and atrial fibrillation (AF) might be at an increased risk of intracranial hemorrhage (ICH) due to anticoagulation (AC). Our aim was to assess this risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our institution\u2019s database (from 2005 to 2017) was screened for patients with GBM or MET and AF with an indication for AC according to their CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>VASc stroke risk score (\u2265\u20092). Required follow-up was at least 3\u00a0months. AC was either performed with heparins, phenprocoumon or non-Vitamin K antagonist oral anticoagulants. Applying the propensity score approach, patient cohorts (matched according to primary tumor, age, sex) were generated (GBM [or MET] with AF\u2009\u00b1\u2009AC, GBM [or MET] without AF\/AC, no GBM [or MET] but AF on AC). ICH was defined as clinical deterioration caused by new blood on imaging. A log rank test was performed to compare the risk for ICH between the three groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 104 patients were identified of which 49 with GBM (37% on AC) and 37 with MET (46% on AC) were successfully matched. Median follow up was 8.6 and 7.2\u00a0months, respectively. ICH occurred in 10.2% of GBM\u2009+\u2009AF and 12.2% GBM-AF, whereas 8% of patients with AF on AC suffered ICH (p\u2009=\u20090.076). 13.5% of patients with MET\u2009+\u2009AF had ICHs, in the controls it was 16% for MET-AF and 8% for AF on AC (p\u2009=\u20090.11).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>AC did not seem to influence the incidence of ICH in patients with glioblastoma or brain metastases within follow up of just under 9\u00a0months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-021-03716-8","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T18:03:53Z","timestamp":1614967433000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?"],"prefix":"10.1007","volume":"152","author":[{"given":"Sina","family":"Burth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Ohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea","family":"Kronsteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinhard","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"L\u00f6w","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Riedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Laible","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Berberich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Dr\u00fcschler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timolaos","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Wick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-6647","authenticated-orcid":false,"given":"Simon","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"issue":"Supplement_5","key":"3716_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro-oncology 21(Supplement_5):v1\u2013v100. https:\/\/doi.org\/10.1093\/neuonc\/noz150","journal-title":"Neuro-oncology"},{"issue":"14","key":"3716_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"issue":"1","key":"3716_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","volume":"124","author":"S Yust-Katz","year":"2015","unstructured":"Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS (2015) Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 124(1):87\u201394. https:\/\/doi.org\/10.1007\/s11060-015-1805-2","journal-title":"J Neurooncol"},{"issue":"18","key":"3716_CR4","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18):2370\u20132375. https:\/\/doi.org\/10.1001\/jama.285.18.2370","journal-title":"JAMA"},{"issue":"12","key":"3716_CR5","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","volume":"16","author":"J Thaler","year":"2014","unstructured":"Thaler J, Ay C, Kaider A, Reitter EM, Haselbock J, Mannhalter C, Zielinski C, Marosi C, Pabinger I (2014) Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncology 16(12):1645\u20131651. https:\/\/doi.org\/10.1093\/neuonc\/nou106","journal-title":"Neuro-oncology"},{"key":"3716_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","volume":"137","author":"NC Edwin","year":"2016","unstructured":"Edwin NC, Khoury MN, Sohal D, McCrae KR, Ahluwalia MS, Khorana AA (2016) Recurrent venous thromboembolism in glioblastoma. Thromb Res 137:184\u2013188. https:\/\/doi.org\/10.1016\/j.thromres.2015.11.027","journal-title":"Thromb Res"},{"issue":"Suppl 4","key":"3716_CR7","doi-asserted-by":"publisher","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","volume":"14","author":"JR Perry","year":"2012","unstructured":"Perry JR (2012) Thromboembolic disease in patients with high-grade glioma. Neuro-oncology 14(Suppl 4):iv73\u2013iv80. https:\/\/doi.org\/10.1093\/neuonc\/nos197","journal-title":"Neuro-oncology"},{"issue":"9","key":"3716_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/jth.13387","volume":"14","author":"JI Zwicker","year":"2016","unstructured":"Zwicker JI, Karp Leaf R, Carrier M (2016) A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 14(9):1736\u20131740. https:\/\/doi.org\/10.1111\/jth.13387","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3716_CR9","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712\u20131723. https:\/\/doi.org\/10.1182\/blood-2013-04-460121","journal-title":"Blood"},{"issue":"10","key":"3716_CR10","first-page":"4309","volume":"29","author":"E Pan","year":"2009","unstructured":"Pan E, Tsai JS, Mitchell SB (2009) Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res 29(10):4309\u20134313","journal-title":"Anticancer Res"},{"key":"3716_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clineuro.2015.01.006","volume":"134","author":"G Ening","year":"2015","unstructured":"Ening G, Osterheld F, Capper D, Schmieder K, Brenke C (2015) Risk factors for glioblastoma therapy associated complications. Clin Neurol Neurosurg 134:55\u201359. https:\/\/doi.org\/10.1016\/j.clineuro.2015.01.006","journal-title":"Clin Neurol Neurosurg"},{"issue":"25","key":"3716_CR12","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","volume":"129","author":"C Mantia","year":"2017","unstructured":"Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI (2017) Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 129(25):3379\u20133385. https:\/\/doi.org\/10.1182\/blood-2017-02-767285","journal-title":"Blood"},{"issue":"7","key":"3716_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1212\/wnl.27.7.650","volume":"27","author":"TI Mandybur","year":"1977","unstructured":"Mandybur TI (1977) Intracranial hemorrhage caused by metastatic tumors. Neurology 27(7):650\u2013655. https:\/\/doi.org\/10.1212\/wnl.27.7.650","journal-title":"Neurology"},{"issue":"3","key":"3716_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jocn.2008.05.010","volume":"16","author":"MJ Hsieh","year":"2009","unstructured":"Hsieh MJ, Lu CH, Tsai NW, Lui CC, Chuang YC, Huang CR, Chen SF, Chang CC, Chang HW, Chang WN (2009) Prediction, clinical characteristics and prognosis of intracerebral hemorrhage in hepatocellular carcinoma patients with intracerebral metastasis. J Clin Neurosci 16(3):394\u2013398. https:\/\/doi.org\/10.1016\/j.jocn.2008.05.010","journal-title":"J Clin Neurosci"},{"issue":"4","key":"3716_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/CMR.0b013e328353efd8","volume":"22","author":"G Alvarado","year":"2012","unstructured":"Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA (2012) Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310\u2013315. https:\/\/doi.org\/10.1097\/CMR.0b013e328353efd8","journal-title":"Melanoma Res"},{"issue":"4","key":"3716_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","volume":"126","author":"J Donato","year":"2015","unstructured":"Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI (2015) Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 126(4):494\u2013499. https:\/\/doi.org\/10.1182\/blood-2015-02-626788","journal-title":"Blood"},{"issue":"4","key":"3716_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1634\/theoncologist.2017-0274","volume":"23","author":"RJ Lin","year":"2018","unstructured":"Lin RJ, Green DL, Shah GL (2018) Therapeutic anticoagulation in patients with primary brain tumors or secondary brain metastasis. Oncologist 23(4):468\u2013473. https:\/\/doi.org\/10.1634\/theoncologist.2017-0274","journal-title":"Oncologist"},{"issue":"2","key":"3716_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11239-016-1434-4","volume":"43","author":"CM Rojas-Hernandez","year":"2017","unstructured":"Rojas-Hernandez CM, Oo TH, Garcia-Perdomo HA (2017) Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. J Thromb Thrombolysis 43(2):233\u2013240. https:\/\/doi.org\/10.1007\/s11239-016-1434-4","journal-title":"J Thromb Thrombolysis"},{"issue":"5\u20136","key":"3716_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000381728","volume":"39","author":"S Horstmann","year":"2015","unstructured":"Horstmann S, Rizos T, Saribas M, Efthymiou E, Rauch G, Veltkamp R (2015) Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation. Cerebrovasc Dis 39(5\u20136):325\u2013331. https:\/\/doi.org\/10.1159\/000381728","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"3716_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"issue":"1","key":"3716_CR21","doi-asserted-by":"publisher","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","volume":"8","author":"UN Chukwueke","year":"2019","unstructured":"Chukwueke UN, Wen PY (2019) Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 8(1):CNS28. https:\/\/doi.org\/10.2217\/cns-2018-0007","journal-title":"CNS Oncol"},{"issue":"8","key":"3716_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"3","key":"3716_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1474-4422(08)70041-3","volume":"7","author":"CS Kidwell","year":"2008","unstructured":"Kidwell CS, Wintermark M (2008) Imaging of intracranial haemorrhage. Lancet Neurol 7(3):256\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(08)70041-3","journal-title":"Lancet Neurol"},{"key":"3716_CR24","unstructured":"R Core Team (2020) R: a language and environment for statistical computing"},{"issue":"7","key":"3716_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/neuonc\/nov300","volume":"18","author":"F Saran","year":"2016","unstructured":"Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R (2016) Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-oncology 18(7):991\u20131001. https:\/\/doi.org\/10.1093\/neuonc\/nov300","journal-title":"Neuro-oncology"},{"issue":"7","key":"3716_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/jnnp.74.7.908","volume":"74","author":"H Suzuki","year":"2003","unstructured":"Suzuki H, Toyoda S, Muramatsu M, Shimizu T, Kojima T, Taki W (2003) Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear accelerator. J Neurol Neurosurg Psychiatry 74(7):908\u2013912. https:\/\/doi.org\/10.1136\/jnnp.74.7.908","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"3716_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Ruda R, Tonn JC, Weber DC, Weller M (2017) Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-oncology 19(2):162\u2013174. https:\/\/doi.org\/10.1093\/neuonc\/now241","journal-title":"Neuro-oncology"},{"issue":"1","key":"3716_CR28","doi-asserted-by":"publisher","first-page":"vdaa015","DOI":"10.1093\/noajnl\/vdaa015","volume":"2","author":"A Lauko","year":"2020","unstructured":"Lauko A, Rauf Y, Ahluwalia MS (2020) Medical management of brain metastases. Neurooncol Adv 2(1):vdaa015. https:\/\/doi.org\/10.1093\/noajnl\/vdaa015","journal-title":"Neurooncol Adv"},{"issue":"5","key":"3716_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17(5):279\u2013299. https:\/\/doi.org\/10.1038\/s41571-019-0320-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3716_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"issue":"1","key":"3716_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/asheducation-2016.1.196","volume":"2016","author":"MB Streiff","year":"2016","unstructured":"Streiff MB (2016) Thrombosis in the setting of cancer. Hematol Am Soc Hematol Educ Program 2016(1):196\u2013205. https:\/\/doi.org\/10.1182\/asheducation-2016.1.196","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03716-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T17:17:33Z","timestamp":1619716653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03716-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03716-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Outside this study, Dr. Nagel reports personal fees from Brainomix, Boehringer Ingelheim and BMS Pfizer and grants from Cerenovus. Dr. Rizos reports consulting honoraria, speakers\u2019 honoraria and travel support from Bristol-Myers Squibb\/Pfizer, Boehringer-Ingelheim, Bayer HealthCare and DaichiiSankyo, outside of the present work. The other authors have stated explicitly that there are no conflict of interest in connection with this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Inclusion of patients into this analysis is covered by a local Heidelberg ethics vote (No. S307\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}